Primary Biliary Cirrhosis Drug Industry Research Report 2025
Description
Summary
According to APO Research, the global Primary Biliary Cirrhosis Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Primary Biliary Cirrhosis Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Primary Biliary Cirrhosis Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Primary Biliary Cirrhosis Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Primary Biliary Cirrhosis Drug include AlbireoPharma, CymaBay Therapeutics, Inc., Dr. Falk Pharma GmbH, Enanta Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., MediGene AG, NGM Biopharmaceuticals, Inc., Virobay Inc. and GlaxoSmithKline Plc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Primary Biliary Cirrhosis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Biliary Cirrhosis Drug.
The report will help the Primary Biliary Cirrhosis Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Primary Biliary Cirrhosis Drug market size, estimations, and forecasts are provided in terms of sales volume (W Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Primary Biliary Cirrhosis Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Primary Biliary Cirrhosis Drug Segment by Company
AlbireoPharma
CymaBay Therapeutics, Inc.
Dr. Falk Pharma GmbH
Enanta Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
MediGene AG
NGM Biopharmaceuticals, Inc.
Virobay Inc.
GlaxoSmithKline Plc
Johnson & Johnson
Primary Biliary Cirrhosis Drug Segment by Type
Budesonide
NGM-282
MBX-8025
GSK-2330672
FFP-104
Others
Primary Biliary Cirrhosis Drug Segment by Application
Clinic
Hospital
Others
Primary Biliary Cirrhosis Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Primary Biliary Cirrhosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Primary Biliary Cirrhosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Primary Biliary Cirrhosis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Primary Biliary Cirrhosis Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Primary Biliary Cirrhosis Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Primary Biliary Cirrhosis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global Primary Biliary Cirrhosis Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Primary Biliary Cirrhosis Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Primary Biliary Cirrhosis Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Primary Biliary Cirrhosis Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Primary Biliary Cirrhosis Drug include AlbireoPharma, CymaBay Therapeutics, Inc., Dr. Falk Pharma GmbH, Enanta Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., MediGene AG, NGM Biopharmaceuticals, Inc., Virobay Inc. and GlaxoSmithKline Plc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Primary Biliary Cirrhosis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Biliary Cirrhosis Drug.
The report will help the Primary Biliary Cirrhosis Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Primary Biliary Cirrhosis Drug market size, estimations, and forecasts are provided in terms of sales volume (W Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Primary Biliary Cirrhosis Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Primary Biliary Cirrhosis Drug Segment by Company
AlbireoPharma
CymaBay Therapeutics, Inc.
Dr. Falk Pharma GmbH
Enanta Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
MediGene AG
NGM Biopharmaceuticals, Inc.
Virobay Inc.
GlaxoSmithKline Plc
Johnson & Johnson
Primary Biliary Cirrhosis Drug Segment by Type
Budesonide
NGM-282
MBX-8025
GSK-2330672
FFP-104
Others
Primary Biliary Cirrhosis Drug Segment by Application
Clinic
Hospital
Others
Primary Biliary Cirrhosis Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Primary Biliary Cirrhosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Primary Biliary Cirrhosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Primary Biliary Cirrhosis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Primary Biliary Cirrhosis Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Primary Biliary Cirrhosis Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Primary Biliary Cirrhosis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
123 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Primary Biliary Cirrhosis Drug Market Size (2020-2031)
- 2.2.2 Global Primary Biliary Cirrhosis Drug Sales (2020-2031)
- 2.2.3 Global Primary Biliary Cirrhosis Drug Market Average Price (2020-2031)
- 2.3 Primary Biliary Cirrhosis Drug by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 Budesonide
- 2.3.3 NGM-282
- 2.3.4 MBX-8025
- 2.3.5 GSK-2330672
- 2.3.6 FFP-104
- 2.3.7 Others
- 2.4 Primary Biliary Cirrhosis Drug by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Others
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Primary Biliary Cirrhosis Drug Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Primary Biliary Cirrhosis Drug Sales (W Units) of Manufacturers (2020-2025)
- 3.3 Global Primary Biliary Cirrhosis Drug Revenue of Manufacturers (2020-2025)
- 3.4 Global Primary Biliary Cirrhosis Drug Average Price by Manufacturers (2020-2025)
- 3.5 Global Primary Biliary Cirrhosis Drug Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Primary Biliary Cirrhosis Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Primary Biliary Cirrhosis Drug, Product Type & Application
- 3.8 Global Manufacturers of Primary Biliary Cirrhosis Drug, Established Date
- 3.9 Global Primary Biliary Cirrhosis Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 AlbireoPharma
- 4.1.1 AlbireoPharma Company Information
- 4.1.2 AlbireoPharma Business Overview
- 4.1.3 AlbireoPharma Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Product Portfolio
- 4.1.5 AlbireoPharma Recent Developments
- 4.2 CymaBay Therapeutics, Inc.
- 4.2.1 CymaBay Therapeutics, Inc. Company Information
- 4.2.2 CymaBay Therapeutics, Inc. Business Overview
- 4.2.3 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
- 4.2.5 CymaBay Therapeutics, Inc. Recent Developments
- 4.3 Dr. Falk Pharma GmbH
- 4.3.1 Dr. Falk Pharma GmbH Company Information
- 4.3.2 Dr. Falk Pharma GmbH Business Overview
- 4.3.3 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Portfolio
- 4.3.5 Dr. Falk Pharma GmbH Recent Developments
- 4.4 Enanta Pharmaceuticals, Inc.
- 4.4.1 Enanta Pharmaceuticals, Inc. Company Information
- 4.4.2 Enanta Pharmaceuticals, Inc. Business Overview
- 4.4.3 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
- 4.4.5 Enanta Pharmaceuticals, Inc. Recent Developments
- 4.5 Intercept Pharmaceuticals, Inc.
- 4.5.1 Intercept Pharmaceuticals, Inc. Company Information
- 4.5.2 Intercept Pharmaceuticals, Inc. Business Overview
- 4.5.3 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
- 4.5.5 Intercept Pharmaceuticals, Inc. Recent Developments
- 4.6 MediGene AG
- 4.6.1 MediGene AG Company Information
- 4.6.2 MediGene AG Business Overview
- 4.6.3 MediGene AG Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 MediGene AG Primary Biliary Cirrhosis Drug Product Portfolio
- 4.6.5 MediGene AG Recent Developments
- 4.7 NGM Biopharmaceuticals, Inc.
- 4.7.1 NGM Biopharmaceuticals, Inc. Company Information
- 4.7.2 NGM Biopharmaceuticals, Inc. Business Overview
- 4.7.3 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
- 4.7.5 NGM Biopharmaceuticals, Inc. Recent Developments
- 4.8 Virobay Inc.
- 4.8.1 Virobay Inc. Company Information
- 4.8.2 Virobay Inc. Business Overview
- 4.8.3 Virobay Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Virobay Inc. Primary Biliary Cirrhosis Drug Product Portfolio
- 4.8.5 Virobay Inc. Recent Developments
- 4.9 GlaxoSmithKline Plc
- 4.9.1 GlaxoSmithKline Plc Company Information
- 4.9.2 GlaxoSmithKline Plc Business Overview
- 4.9.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Portfolio
- 4.9.5 GlaxoSmithKline Plc Recent Developments
- 4.10 Johnson & Johnson
- 4.10.1 Johnson & Johnson Company Information
- 4.10.2 Johnson & Johnson Business Overview
- 4.10.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 Johnson & Johnson Primary Biliary Cirrhosis Drug Product Portfolio
- 4.10.5 Johnson & Johnson Recent Developments
- 5 Global Primary Biliary Cirrhosis Drug Market Scenario by Region
- 5.1 Global Primary Biliary Cirrhosis Drug Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Primary Biliary Cirrhosis Drug Sales by Region: 2020-2031
- 5.2.1 Global Primary Biliary Cirrhosis Drug Sales by Region: 2020-2025
- 5.2.2 Global Primary Biliary Cirrhosis Drug Sales by Region: 2026-2031
- 5.3 Global Primary Biliary Cirrhosis Drug Revenue by Region: 2020-2031
- 5.3.1 Global Primary Biliary Cirrhosis Drug Revenue by Region: 2020-2025
- 5.3.2 Global Primary Biliary Cirrhosis Drug Revenue by Region: 2026-2031
- 5.4 North America Primary Biliary Cirrhosis Drug Market Facts & Figures by Country
- 5.4.1 North America Primary Biliary Cirrhosis Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Primary Biliary Cirrhosis Drug Sales by Country (2020-2031)
- 5.4.3 North America Primary Biliary Cirrhosis Drug Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Primary Biliary Cirrhosis Drug Market Facts & Figures by Country
- 5.5.1 Europe Primary Biliary Cirrhosis Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Primary Biliary Cirrhosis Drug Sales by Country (2020-2031)
- 5.5.3 Europe Primary Biliary Cirrhosis Drug Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Primary Biliary Cirrhosis Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Primary Biliary Cirrhosis Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Primary Biliary Cirrhosis Drug Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Primary Biliary Cirrhosis Drug Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Primary Biliary Cirrhosis Drug Market Facts & Figures by Country
- 5.7.1 South America Primary Biliary Cirrhosis Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Primary Biliary Cirrhosis Drug Sales by Country (2020-2031)
- 5.7.3 South America Primary Biliary Cirrhosis Drug Revenue by Country (2020-2031)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Primary Biliary Cirrhosis Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Primary Biliary Cirrhosis Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Primary Biliary Cirrhosis Drug Revenue by Country (2020-2031)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
- 6 Segment by Type
- 6.1 Global Primary Biliary Cirrhosis Drug Sales by Type (2020-2031)
- 6.1.1 Global Primary Biliary Cirrhosis Drug Sales by Type (2020-2031) & (W Units)
- 6.1.2 Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2020-2031)
- 6.2 Global Primary Biliary Cirrhosis Drug Revenue by Type (2020-2031)
- 6.2.1 Global Primary Biliary Cirrhosis Drug Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2020-2031)
- 6.3 Global Primary Biliary Cirrhosis Drug Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Primary Biliary Cirrhosis Drug Sales by Application (2020-2031)
- 7.1.1 Global Primary Biliary Cirrhosis Drug Sales by Application (2020-2031) & (W Units)
- 7.1.2 Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2020-2031)
- 7.2 Global Primary Biliary Cirrhosis Drug Revenue by Application (2020-2031)
- 7.2.1 Global Primary Biliary Cirrhosis Drug Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2020-2031)
- 7.3 Global Primary Biliary Cirrhosis Drug Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Primary Biliary Cirrhosis Drug Value Chain Analysis
- 8.1.1 Primary Biliary Cirrhosis Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Primary Biliary Cirrhosis Drug Production Mode & Process
- 8.2 Primary Biliary Cirrhosis Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Primary Biliary Cirrhosis Drug Distributors
- 8.2.3 Primary Biliary Cirrhosis Drug Customers
- 9 Global Primary Biliary Cirrhosis Drug Analyzing Market Dynamics
- 9.1 Primary Biliary Cirrhosis Drug Industry Trends
- 9.2 Primary Biliary Cirrhosis Drug Industry Drivers
- 9.3 Primary Biliary Cirrhosis Drug Industry Opportunities and Challenges
- 9.4 Primary Biliary Cirrhosis Drug Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Primary Biliary Cirrhosis Drug Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
- Table 6. Global Primary Biliary Cirrhosis Drug Sales (W Units) of Manufacturers (2020-2025)
- Table 7. Global Primary Biliary Cirrhosis Drug Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global Primary Biliary Cirrhosis Drug Revenue of Manufacturers (2020-2025)
- Table 9. Global Primary Biliary Cirrhosis Drug Revenue Share by Manufacturers (2020-2025)
- Table 10. Global Market Primary Biliary Cirrhosis Drug Average Price (US$/Unit) of Manufacturers (2020-2025)
- Table 11. Global Primary Biliary Cirrhosis Drug Industry Ranking, 2023 VS 2024 VS 2025
- Table 12. Global Manufacturers of Primary Biliary Cirrhosis Drug, Manufacturing Sites & Headquarters
- Table 13. Global Manufacturers of Primary Biliary Cirrhosis Drug, Product Type & Application
- Table 14. Global Primary Biliary Cirrhosis Drug Manufacturers Established Date
- Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16. Global Primary Biliary Cirrhosis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18. AlbireoPharma Company Information
- Table 19. AlbireoPharma Business Overview
- Table 20. AlbireoPharma Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 21. AlbireoPharma Primary Biliary Cirrhosis Drug Product Portfolio
- Table 22. AlbireoPharma Recent Developments
- Table 23. CymaBay Therapeutics, Inc. Company Information
- Table 24. CymaBay Therapeutics, Inc. Business Overview
- Table 25. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 26. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
- Table 27. CymaBay Therapeutics, Inc. Recent Developments
- Table 28. Dr. Falk Pharma GmbH Company Information
- Table 29. Dr. Falk Pharma GmbH Business Overview
- Table 30. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 31. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Portfolio
- Table 32. Dr. Falk Pharma GmbH Recent Developments
- Table 33. Enanta Pharmaceuticals, Inc. Company Information
- Table 34. Enanta Pharmaceuticals, Inc. Business Overview
- Table 35. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 36. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
- Table 37. Enanta Pharmaceuticals, Inc. Recent Developments
- Table 38. Intercept Pharmaceuticals, Inc. Company Information
- Table 39. Intercept Pharmaceuticals, Inc. Business Overview
- Table 40. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 41. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
- Table 42. Intercept Pharmaceuticals, Inc. Recent Developments
- Table 43. MediGene AG Company Information
- Table 44. MediGene AG Business Overview
- Table 45. MediGene AG Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 46. MediGene AG Primary Biliary Cirrhosis Drug Product Portfolio
- Table 47. MediGene AG Recent Developments
- Table 48. NGM Biopharmaceuticals, Inc. Company Information
- Table 49. NGM Biopharmaceuticals, Inc. Business Overview
- Table 50. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 51. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
- Table 52. NGM Biopharmaceuticals, Inc. Recent Developments
- Table 53. Virobay Inc. Company Information
- Table 54. Virobay Inc. Business Overview
- Table 55. Virobay Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 56. Virobay Inc. Primary Biliary Cirrhosis Drug Product Portfolio
- Table 57. Virobay Inc. Recent Developments
- Table 58. GlaxoSmithKline Plc Company Information
- Table 59. GlaxoSmithKline Plc Business Overview
- Table 60. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 61. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Portfolio
- Table 62. GlaxoSmithKline Plc Recent Developments
- Table 63. Johnson & Johnson Company Information
- Table 64. Johnson & Johnson Business Overview
- Table 65. Johnson & Johnson Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 66. Johnson & Johnson Primary Biliary Cirrhosis Drug Product Portfolio
- Table 67. Johnson & Johnson Recent Developments
- Table 68. Global Primary Biliary Cirrhosis Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 69. Global Primary Biliary Cirrhosis Drug Sales by Region (2020-2025) & (W Units)
- Table 70. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2020-2025)
- Table 71. Global Primary Biliary Cirrhosis Drug Sales by Region (2026-2031) & (W Units)
- Table 72. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2026-2031)
- Table 73. Global Primary Biliary Cirrhosis Drug Revenue by Region (2020-2025) & (US$ Million)
- Table 74. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2020-2025)
- Table 75. Global Primary Biliary Cirrhosis Drug Revenue by Region (2026-2031) & (US$ Million)
- Table 76. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2026-2031)
- Table 77. North America Primary Biliary Cirrhosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 78. North America Primary Biliary Cirrhosis Drug Sales by Country (2020-2025) & (W Units)
- Table 79. North America Primary Biliary Cirrhosis Drug Sales by Country (2026-2031) & (W Units)
- Table 80. North America Primary Biliary Cirrhosis Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 81. North America Primary Biliary Cirrhosis Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 82. Europe Primary Biliary Cirrhosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 83. Europe Primary Biliary Cirrhosis Drug Sales by Country (2020-2025) & (W Units)
- Table 84. Europe Primary Biliary Cirrhosis Drug Sales by Country (2026-2031) & (W Units)
- Table 85. Europe Primary Biliary Cirrhosis Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 86. Europe Primary Biliary Cirrhosis Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 87. Asia Pacific Primary Biliary Cirrhosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 88. Asia Pacific Primary Biliary Cirrhosis Drug Sales by Country (2020-2025) & (W Units)
- Table 89. Asia Pacific Primary Biliary Cirrhosis Drug Sales by Country (2026-2031) & (W Units)
- Table 90. Asia Pacific Primary Biliary Cirrhosis Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 91. Asia Pacific Primary Biliary Cirrhosis Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 92. South America Primary Biliary Cirrhosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 93. South America Primary Biliary Cirrhosis Drug Sales by Country (2020-2025) & (W Units)
- Table 94. South America Primary Biliary Cirrhosis Drug Sales by Country (2026-2031) & (W Units)
- Table 95. South America Primary Biliary Cirrhosis Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 96. South America Primary Biliary Cirrhosis Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 97. Middle East and Africa Primary Biliary Cirrhosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 98. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country (2020-2025) & (W Units)
- Table 99. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country (2026-2031) & (W Units)
- Table 100. Middle East and Africa Primary Biliary Cirrhosis Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 101. Middle East and Africa Primary Biliary Cirrhosis Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 102. Global Primary Biliary Cirrhosis Drug Sales by Type (2020-2025) & (W Units)
- Table 103. Global Primary Biliary Cirrhosis Drug Sales by Type (2026-2031) & (W Units)
- Table 104. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2020-2025)
- Table 105. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2026-2031)
- Table 106. Global Primary Biliary Cirrhosis Drug Revenue by Type (2020-2025) & (US$ Million)
- Table 107. Global Primary Biliary Cirrhosis Drug Revenue by Type (2026-2031) & (US$ Million)
- Table 108. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2020-2025)
- Table 109. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2026-2031)
- Table 110. Global Primary Biliary Cirrhosis Drug Price by Type (2020-2025) & (US$/Unit)
- Table 111. Global Primary Biliary Cirrhosis Drug Price by Type (2026-2031) & (US$/Unit)
- Table 112. Global Primary Biliary Cirrhosis Drug Sales by Application (2020-2025) & (W Units)
- Table 113. Global Primary Biliary Cirrhosis Drug Sales by Application (2026-2031) & (W Units)
- Table 114. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2020-2025)
- Table 115. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2026-2031)
- Table 116. Global Primary Biliary Cirrhosis Drug Revenue by Application (2020-2025) & (US$ Million)
- Table 117. Global Primary Biliary Cirrhosis Drug Revenue by Application (2026-2031) & (US$ Million)
- Table 118. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2020-2025)
- Table 119. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2026-2031)
- Table 120. Global Primary Biliary Cirrhosis Drug Price by Application (2020-2025) & (US$/Unit)
- Table 121. Global Primary Biliary Cirrhosis Drug Price by Application (2026-2031) & (US$/Unit)
- Table 122. Key Raw Materials
- Table 123. Raw Materials Key Suppliers
- Table 124. Primary Biliary Cirrhosis Drug Distributors List
- Table 125. Primary Biliary Cirrhosis Drug Customers List
- Table 126. Primary Biliary Cirrhosis Drug Industry Trends
- Table 127. Primary Biliary Cirrhosis Drug Industry Drivers
- Table 128. Primary Biliary Cirrhosis Drug Industry Restraints
- Table 129. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Primary Biliary Cirrhosis Drug Product Image
- Figure 5. Global Primary Biliary Cirrhosis Drug Revenue (US$ Million), 2020 VS 2024 VS 2031
- Figure 6. Global Primary Biliary Cirrhosis Drug Market Size (2020-2031) & (US$ Million)
- Figure 7. Global Primary Biliary Cirrhosis Drug Sales (2020-2031) & (W Units)
- Figure 8. Global Primary Biliary Cirrhosis Drug Average Price (US$/Unit) & (2020-2031)
- Figure 9. Budesonide Product Image
- Figure 10. NGM-282 Product Image
- Figure 11. MBX-8025 Product Image
- Figure 12. GSK-2330672 Product Image
- Figure 13. FFP-104 Product Image
- Figure 14. Others Product Image
- Figure 15. Clinic Product Image
- Figure 16. Hospital Product Image
- Figure 17. Others Product Image
- Figure 18. Global Primary Biliary Cirrhosis Drug Revenue Share by Manufacturers in 2024
- Figure 19. Global Manufacturers of Primary Biliary Cirrhosis Drug, Manufacturing Sites & Headquarters
- Figure 20. Global Top 5 and 10 Primary Biliary Cirrhosis Drug Players Market Share by Revenue in 2024
- Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 22. Global Primary Biliary Cirrhosis Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Figure 23. Global Primary Biliary Cirrhosis Drug Sales by Region in 2024
- Figure 24. Global Primary Biliary Cirrhosis Drug Revenue by Region in 2024
- Figure 25. North America Primary Biliary Cirrhosis Drug Market Size by Country in 2024
- Figure 26. North America Primary Biliary Cirrhosis Drug Sales Market Share by Country (2020-2031)
- Figure 27. North America Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2020-2031)
- Figure 28. United States Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 29. Canada Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 30. Europe Primary Biliary Cirrhosis Drug Market Size by Country in 2024
- Figure 31. Europe Primary Biliary Cirrhosis Drug Sales Market Share by Country (2020-2031)
- Figure 32. Europe Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2020-2031)
- Figure 33. Germany Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 34. France Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 35. U.K. Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 36. Italy Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 37. Netherlands Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 38. Nordic Countries Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 39. Asia Pacific Primary Biliary Cirrhosis Drug Market Size by Country in 2024
- Figure 40. Asia Pacific Primary Biliary Cirrhosis Drug Sales Market Share by Country (2020-2031)
- Figure 41. Asia Pacific Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2020-2031)
- Figure 42. China Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 43. Japan Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 44. South Korea Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 45. India Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 46. Australia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 47. China Taiwan Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 48. Southeast Asia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 49. Southeast Asia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 50. South America Primary Biliary Cirrhosis Drug Market Size by Country in 2024
- Figure 51. South America Primary Biliary Cirrhosis Drug Sales Market Share by Country (2020-2031)
- Figure 52. South America Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2020-2031)
- Figure 53. Mexico Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 54. Brazil Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 55. Argentina Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 56. Middle East and Africa Primary Biliary Cirrhosis Drug Market Size by Country in 2024
- Figure 57. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share by Country (2020-2031)
- Figure 58. Middle East and Africa Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2020-2031)
- Figure 59. Turkey Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 60. Saudi Arabia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 61. UAE Primary Biliary Cirrhosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 62. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2020-2031)
- Figure 63. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2020-2031)
- Figure 64. Global Primary Biliary Cirrhosis Drug Price (US$/Unit) by Type (2020-2031)
- Figure 65. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2020-2031)
- Figure 66. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2020-2031)
- Figure 67. Global Primary Biliary Cirrhosis Drug Price (US$/Unit) by Application (2020-2031)
- Figure 68. Primary Biliary Cirrhosis Drug Value Chain
- Figure 69. Primary Biliary Cirrhosis Drug Production Mode & Process
- Figure 70. Direct Comparison with Distribution Share
- Figure 71. Distributors Profiles
- Figure 72. Primary Biliary Cirrhosis Drug Industry Opportunities and Challenges
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
